FDA Hits Suzhou Amerigen for Inadequate Investigations, Quality Controls

Drug Industry Daily
A A
The FDA issued a Form 483 to drug manufacturer Amerigen for insufficient record-keeping and quality controls following a November 2016 inspection of the company’s Suzhou, China, facility.

To View This Article:

Login

Subscribe To Drug Industry Daily